FDA grants approval of Enhertu (trastuzumab deruxtecan) for HER2-positive metastatic gastric cancer

Approval is based on results of the phase II DESTINY-Gastric01 trial (n=126) which demonstrated greater overall survival (12.5 vs 8.4 months; HR, 0.59; 95% CI 0.39-0.88; p=0.0097) and higher objective response rate vs chemotherapy (40.5% vs 11.3%).

Source:

Biospace Inc.